A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis

A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis

Steroid-resistant focal segmental glomerulosclerosis (SR-FSGS) is a common glomerulopathy associated with nephrotic range proteinuria. Treatment goals are reduction in proteinuria, which can delay end-stage renal disease. Methods: Patients with SR-FSGS were enrolled in a randomized, double-blind pla...

Full description

Bibliographic Details
Main Authors: Flavio Vincenti, Fernando C. Fervenza, Kirk N. Campbell, Montserrat Diaz, Loreto Gesualdo, Peter Nelson, Manuel Praga, Jai Radhakrishnan, Lorenz Sellin, Ajay Singh, Denyse Thornley-Brown, Francisco Veríssimo Veronese, Beverly Accomando, Sara Engstrand, Steven Ledbetter, Julie Lin, John Neylan, James Tumlin
Format: Article
Language:English
Published: Elsevier 2017-09-01
Series:Kidney International Reports
Subjects:
fresolimumab
monoclonal antibody
proteinuria
steroid-resistant primary focal segmental glomerulosclerosis
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024917300694

Internet

http://www.sciencedirect.com/science/article/pii/S2468024917300694

Similar Items